Removing fallopian tubes, a procedure known as opportunistic salpingectomy, may help prevent the development of ovarian cancer, according to a consensus statement from the Ovarian Cancer Research ...

The approval is based on the results of Corcept’s Phase 3 ROSELLA trial, which showed improvements in both progression-free ...

FDA authorization covers platinum-resistant disease after 1–3 prior lines, with mandatory prior bevacizumab exposure, ...

Shares of Corcept Therapeutics (NASDAQ:CORT) surged about 40% on Wednesday after the U.S. Food and Drug Administration (FDA) ...

“Knowledge is power,” says Samantha Carlucci, 26. The Ravena, New York, resident recently had a hysterectomy that included removing her fallopian tubes – and believes it saved her life. The Ovarian ...

The new guidance from the Ovarian Cancer Research Alliance comes after the organization found that early screening and detection attempts were not effective in preventing deaths The Ovarian Cancer ...

Because there is no effective screening method to catch ovarian cancer at an early stage, most diagnoses occur when the cancer has reached its later stages. As a result, only about half of women with ...

NEW YORK - Ovarian cancer is the fifth leading cause of cancer death in women in the United States, according to the American Cancer Society. Some doctors have renewed calls for some women to remove ...

Removing fallopian tubes, a procedure known as opportunistic salpingectomy, may help reduce the risk of developing ovarian cancer, according to a consensus statement from the Ovarian Cancer Research ...

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Fallopian Tube Cancer Market - A Global and Regional Analysis: Focus on Type, Treatment Type, End User, and Region, 2025-2035" report has been added to ...

Researchers at the University of Pittsburgh have identified a novel trigger of a deadly form of ovarian cancer. Discovery of a subset of high-risk progenitor cells that reside in fallopian tube ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...